The average P/S ratio for VRCA's competitors is 1.14, providing a benchmark for relative valuation. Verrica Pharmaceuticals Inc Corp (VRCA) exhibits a P/S ratio of 2.42, which is 113.09% above the industry average. Given its robust revenue growth of -10.12%, this premium appears unsustainable.